CROSSWICKS, N.J.--(BUSINESS WIRE)--The Myelodysplastic Syndromes (MDS) Foundation applauds the European Commission’s approval of VIDAZA (azacitidine) as an important advance for MDS patients in Europe. Vidaza represents an entirely new approach to treating cancer- it works by epigenetics, that is it helps restore the normal function of genes that regulate cell growth and development. The results, according to the AZA-001 clinical trial, show that VIDAZA is the first and only drug to show a meaningful survival increase for patients with high-risk MDS, and it can significantly reduce their dependence on blood transfusions. This is the largest international Phase III controlled study ever conducted in higher-risk MDS.
